In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey
dc.authorid | 0000-0001-8646-2203 | en_US |
dc.authorid | 0000-0001-7966-3234 | en_US |
dc.authorid | 0000-0002-9400-0997 | en_US |
dc.authorid | 0000-0002-2081-4664 | en_US |
dc.authorid | 0000-0002-8163-1386 | en_US |
dc.authorid | 0000-0002-6054-9244 | en_US |
dc.authorid | 0000-0003-0442-5981 | en_US |
dc.contributor.author | Yıldırım, Figen Sarıgül | |
dc.contributor.author | Üser, Ülkü | |
dc.contributor.author | Sarı, Nagehan Didem | |
dc.contributor.author | Kurtaran, Behice | |
dc.contributor.author | Önlen, Yusuf | |
dc.contributor.author | Can, Güray | |
dc.contributor.author | Sırmatel, Fatma | |
dc.date.accessioned | 2023-09-11T08:38:07Z | |
dc.date.available | 2023-09-11T08:38:07Z | |
dc.date.issued | 2022 | en_US |
dc.department | BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naive patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis. | en_US |
dc.identifier.citation | Yıldırım, F. S., Üser, Ü., Sarı, N. D., Kurtaran, B., Önlen, Y., Şenateş, E., ... & Tabak, F. (2022). In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. The Turkish Journal of Gastroenterology, 33(11), 971. | en_US |
dc.identifier.doi | 10.5152/tjg.2022.21834 | |
dc.identifier.endpage | 978 | en_US |
dc.identifier.issn | 2148-5607 | |
dc.identifier.issue | 11 | en_US |
dc.identifier.pmid | 36415900 | en_US |
dc.identifier.scopus | 2-s2.0-85142524509 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 971 | en_US |
dc.identifier.trdizinid | 1175267 | en_US |
dc.identifier.uri | http://dx.doi.org/10.5152/tjg.2022.21834 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/11689 | |
dc.identifier.volume | 33 | en_US |
dc.identifier.wos | WOS:000898674900009 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | TR-Dizin | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Can, Güray | |
dc.institutionauthor | Sırmatel, Fatma | |
dc.language.iso | en | en_US |
dc.publisher | AVES | en_US |
dc.relation.ispartof | Turkish Journal of Gastroenterology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Drug Therapy | en_US |
dc.subject | Drug Users | en_US |
dc.subject | Hepatitis C Virus | en_US |
dc.subject | Opioid Agonist Treatment | en_US |
dc.subject | Virus-Infection | en_US |
dc.subject | Genotype Distribution | en_US |
dc.title | In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey | en_US |
dc.type | Article | en_US |